0000950170-24-026098.txt : 20240305
0000950170-24-026098.hdr.sgml : 20240305
20240305163907
ACCESSION NUMBER: 0000950170-24-026098
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240303
FILED AS OF DATE: 20240305
DATE AS OF CHANGE: 20240305
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Conway Vikki L
CENTRAL INDEX KEY: 0001995297
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-16174
FILM NUMBER: 24721361
MAIL ADDRESS:
STREET 1: C/O TEVA
STREET 2: 5 BASEL STREET, P.O. BOX 3190
CITY: PETACH TIKVA
STATE: L3
ZIP: 4951033
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: TEVA PHARMACEUTICAL INDUSTRIES LTD
CENTRAL INDEX KEY: 0000818686
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 000000000
STATE OF INCORPORATION: L3
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: TEVA PHARMACEUTICAL INDUSTRIES LIMITED
STREET 2: 124 DVORA HANEVI'A ST.
CITY: TEL AVIV
STATE: L3
ZIP: 6944020
BUSINESS PHONE: 972 (3) 914-8213
MAIL ADDRESS:
STREET 1: TEVA PHARMACEUTICAL INDUSTRIES LIMITED
STREET 2: 124 DVORA HANEVI'A ST.
CITY: TEL AVIV
STATE: L3
ZIP: 6944020
4
1
ownership.xml
4
X0508
4
2024-03-03
0000818686
TEVA PHARMACEUTICAL INDUSTRIES LTD
TEVA
0001995297
Conway Vikki L
C/O TEVA PHARMACEUTICAL INDUSTRIES LTD.
124 DVORA HANEVI'A ST.,
TEL AVIV
L3
6944020
ISRAEL
false
true
false
false
See "Remarks"
true
Ordinary Shares
2024-03-03
4
M
false
5179
A
8107
D
Ordinary Shares
2024-03-04
4
S
false
1490
13.3733
D
6617
D
Ordinary Shares
2024-03-04
4
M
false
7117
A
13734
D
Ordinary Shares
2024-03-04
4
S
false
2042
13.3733
D
11692
D
Restricted Share Units
2024-03-03
4
M
false
5179
0
D
Ordinary Shares
5179
15538
D
Restricted Share Units
2024-03-04
4
M
false
7117
0
D
Ordinary Shares
7117
14237
D
Restricted Share Units
2024-03-04
4
A
false
33482
0
A
Ordinary Shares
33482
33482
D
The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.
The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 21, 2023.
Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted share units listed in Table II.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.25 to $13.445, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price.
Restricted share units were granted on March 3, 2023, with 5,179 vesting on each of March 3, 2024, March 3, 2025 and March 3, 2026, and 5,180 vesting on March 3, 2027.
Restricted share units were granted on March 4, 2022, with 7,117 vesting on each of March 4, 2024 and March 4, 2025, and 7,120 vesting on March 4, 2026.
Restricted share units were granted on March 4, 2024, with 8,370 vesting on each of March 4, 2025, March 4, 2026 and March 4, 2027, and 8,372 vesting on March 4, 2028.
Acting Head of Global Human Resources
/s/ Dov Bergwerk as attorney-in-fact for Vikki L. Conway
2024-03-05